UK updates head and neck cancer service standards:
This article was originally published in Clinica
The UK's Department of Health has published the Head and Neck Measures of the Manual for Cancer Services. The 98-page document features capacity guidelines and other criteria that have implications for specific areas of these services, including imaging and pathology. The standards of care set out in the manual, which was published in 2004 but has now been updated, aim to help NHS providers identify gaps in provision, particularly with regard to safety and clinical and cost-effectiveness. It is based on recommendations issued by the National Institute for Health and Clinical Excellence (Improving Outcomes Guidance), focusing on "aspects of service that are most likely to have a significant impact on health outcomes". Audit-related measures are under development, noted Teresa Moss, director of cancer modernisation, in a cover letter to NHS managers (June 1).
You may also be interested in...
Oxford University/AstraZeneca’s COVID-19 vaccine cuts the spread of the virus by 60%, apart from having 70% efficacy in reducing infections in vaccinated individuals. While that is good news for their Indian partner, Serum Institute, the 90% efficacy shown in a subset due to a dosing error causes a dilemma.
After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.
The US FDA’s decision to ask on device adverse event reports whether the device involved had been serviced by a third party could help the agency as well as device makers, says Ricki Chase, compliance practice director at Lachman Consultant Services.